Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial.

Autor:	Takeru Shiroiwa1 t.shiroiwa@gmail.com, Takashi Fukuda1, Kojiro Shimozuma2, Mitsuko Mouri3, Yasuhiro Hagiwara4, Takuya Kawahara4,5, Shozo Ohsumi6, Yasuo Hozumi7,8, Yoshiaki Sagara9, Yasuo Ohashi10, Hirofumi Mukai11, Shiroiwa, Takeru12 (AUTHOR), Fukuda, Takashi12 (AUTHOR), Shimozuma, Kojiro13 (AUTHOR), Mouri, Mitsuko14 (AUTHOR), Hagiwara, Yasuhiro15 (AUTHOR), Kawahara, Takuya15,16 (AUTHOR), Ohsumi, Shozo17 (AUTHOR), Hozumi, Yasuo18,19 (AUTHOR), Sagara, Yoshiaki20 (AUTHOR)
Zdroj:	BMC Cancer. 11/17/2017, Vol. 17, p1-10. 10p. 5 Charts, 2 Graphs.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu